Namyang reportedly showing 'regret' over the sale of stakes; Hahn & Co. warn of legal action if the deal is delayed or scrapped
S.Korea's KT to produce electronic device for treating neuro disorders
KT Corp. has collaborated with US-based NeuroSigma Inc. to build a business model and technology for electronic medicine to treat neurological disorders, such as attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.
Under the partnership, KTS will support the development of the next version of NeuroSigma's external trigeminal nerve stimulation (eTNS®) system while producing and commercializing the device in South Korea.
NeuoSigma is credited for developing the first device cleared by the US Food and Drug Administration to treat pediatric ADHD--the Monarch external Trigeminal Nerve Stimulation system,
The telecom operator said NeuoSigma's pediatric ADHD electronic treatment has fewer side effects than other existing medication and is set to receive further clearance from the FDA on depression and epilepsy treatment using the technology.